MedTrace Logo

Immunophenotyping of Metastases From Colorectal Cancer

NCT03604926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-11-20

No results posted yet for this study

Summary

Immune therapy represents a promising option for the treatment of an increasing number of malignancies. New immunotherapeutic strategies are currently under development and will be further studied starting from refractory settings of heavily pre-treated mCRC patients. On this basis, a specific immunological characterization of CRC metastasis will be relevant to direct future clinical and pharmacological research.

As surgery is a therapeutic option in the treatment of mCRC, a percentage of mCRC patients undergo to resection of metastasis before or after medical treatment. These tumour samples could be useful to define the immune signature of colorectal metastatic disease.

On the basis of the above reported considerations, an exploratory, prospective, observational study for the immunophenotypical characterization of colorectal cancer metastasis from pre-treated vs chemo-naive patients has been planned.

Conditions

Sponsors & Collaborators

  • Azienda Ospedaliera di Padova

    collaborator OTHER

  • Azienda ULSS 16 Padova

    collaborator OTHER

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-05
Primary Completion
2019-09-15
Completion
2019-09-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604926 on ClinicalTrials.gov